Slide Sourcewww.lipidsonline.org

0

5

10

15

20

25

Kaplan-Meier Curve of Time to Kaplan-Meier Curve of Time to Primary End PointPrimary End Point

Prop

ortio

n of

Eve

nts (

%)

PioglitazonePlacebo

PROactive investigators. Lancet 2005;366:1279-1289.

24882530

23022317

22182215

348345

Pioglitazone (514 events)Placebo (572 events)

21462122

23732413

0 6 12 24 3018 36No. at Risk Time from Randomization (months)

HR = 0.90 (95% CI 0.80-1.02)p = 0.095

Slide Sourcewww.lipidsonline.org

0

5

10

15

20

25

Kaplan-Meier Curve of Time to Kaplan-Meier Curve of Time to Secondary End PointSecondary End Point

Prop

ortio

n of

Eve

nts (

%)

PioglitazonePlacebo

PROactive investigators. Lancet 2005;366:1279-1289.

25362566

24352442

23812371

396390

Pioglitazone (301 events)Placebo (358 events)

23362315

24872504

0 6 12 24 3018 36No. at Risk Time from Randomization (months)

HR = 0.84 (95% CI 0.72-0.98)p = 0.027

Slide Sourcewww.lipidsonline.org

724824Baseline

Change in Posterior-Wall Mean CIMTChange in Posterior-Wall Mean CIMTLS

Mea

n Ch

ange

from

Ba

selin

e, m

m

No. of ObservationsGlimepiridePioglitazone

-0.12

-0.08-0.04

0.00

0.04

0.080.12

0.16

Week

Glimepiride Pioglitazone

186175

170166

186175

186175

Mazzone T et al. JAMA 2006;296:2572-2581.

Slide Sourcewww.lipidsonline.org

724824Baseline

Change in Posterior-Wall Maximum CIMTChange in Posterior-Wall Maximum CIMTLS

Mea

n Ch

ange

from

Ba

selin

e, m

m

No. of ObservationsGlimepiridePioglitazone

-0.02

-0.01

0.00

0.01

0.02

0.03

0.04

Week

Glimepiride Pioglitazone

186175

170166

186175

186175

Mazzone T et al. JAMA 2006;296:2572-2581.